Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.

Abstract:

OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism (glucose transporter-1 [Glut-1]) and genes involved in angiogenesis (i.e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH). PATIENTS AND METHODS:78 formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 36 patients with mCRC. Tumor gene expression was correlated with serum LDH levels from the same group of patients. FFPE tissues were dissected using laser-captured microdissection and analyzed for gene expression using a quantitative real-time RT-PCR method. RESULTS:Intratumoral gene expression of VEGFA and VEGFR1 showed a statistically significant correlation with serum LDH levels (p = 0.006, r = 0.45 and p = 0.004, r = 0.50, respectively). Intratumoral expression of LDHA gene showed a significant correlation with Glut-1, VEGF, HIF1 alpha, HIF2 alpha and VEGFR1 (p = 0.007, r = 0.44; p < 0.001, r = 0.57; p = 0.013, r = 0.41; p = 0.044, r = 0.34; p = 0.026, r = 0.40). Serum LDH levels also correlated with microvessel density analyzed by immunohistochemical analysis. CONCLUSION:The results demonstrated a significant correlation between the intratumoral gene expression of LDHA, HIF1 alpha, HIF2 alpha, Glut-1, NRP1, VEGFA and VEGFR1. Patients with high serum LDH have increased intratumoral gene expression of VEGFA and VEGFR1. The results also support the hypothesis that serum LDH levels may serve as a surrogate marker for activation of the HIF-related genes in the tumor.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

doi

10.2217/14622416.8.12.1705

subject

Has Abstract

pub_date

2007-12-01 00:00:00

pages

1705-13

issue

12

eissn

1462-2416

issn

1744-8042

journal_volume

8

pub_type

杂志文章
  • Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

    abstract:OBJECTIVE:We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS:A total of 45 heavi...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.8.4.319

    authors: Vincenzi B,Santini D,Russo A,Gavasci M,Battistoni F,Dicuonzo G,Rocci L,Rosaria VM,Gebbia N,Tonini G

    更新日期:2007-04-01 00:00:00

  • Epigenetics of cancer progression.

    abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.2.215

    authors: Vucic EA,Brown CJ,Lam WL

    更新日期:2008-02-01 00:00:00

  • A review of consent practices and perspectives for pharmacogenetic testing.

    abstract:AIM:We aimed to understand consent practices for pharmacogenetic (PGx) testing. METHODS:We conducted a literature review and analysis of consent forms from clinical laboratories offering PGx testing. RESULTS:Our review of the literature shows a lack of consensus about the need for and type of informed consent for PGx...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0039

    authors: Haga SB,Mills R

    更新日期:2016-09-01 00:00:00

  • Integrating heterogeneous high-throughput data for meta-dimensional pharmacogenomics and disease-related studies.

    abstract::The current paradigm of human genetics research is to analyze variation of a single data type (i.e., DNA sequence or RNA levels) to detect genes and pathways that underlie complex traits such as disease state or drug response. While these studies have detected thousands of variations that associate with hundreds of co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.11.145

    authors: Holzinger ER,Ritchie MD

    更新日期:2012-01-01 00:00:00

  • BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence.

    abstract:AIM:Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS:The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls u...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.96

    authors: Iamjan SA,Thanoi S,Watiktinkorn P,Nudmamud-Thanoi S,Reynolds GP

    更新日期:2015-01-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.

    abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.10

    authors: Bossé Y

    更新日期:2009-04-01 00:00:00

  • Pharmacogenetics in clinical practice: how far have we come and where are we going?

    abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.52

    authors: Johnson JA

    更新日期:2013-05-01 00:00:00

  • Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.

    abstract::Cancer patients frequently suffer from disease- and treatment-related pain, nausea and depression, which severely reduces patients' quality of life. It is critical that clinicians are aware of drug-gene interactions and recognize the utility of applying pharmacogenetic information to personalize and improve supportive...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.178

    authors: Andersen RL,Johnson DJ,Patel JN

    更新日期:2016-03-01 00:00:00

  • Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.

    abstract:AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.18

    authors: Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

    更新日期:2015-01-01 00:00:00

  • MTRR rs1801394 and its interaction with MTHFR rs1801133 in colorectal cancer: a case-control study and meta-analysis.

    abstract:AIM:This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assess...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs-2017-0030

    authors: Haerian MS,Haerian BS,Molanaei S,Kosari F,Sabeti S,Bidari-Zerehpoosh F,Abdolali E

    更新日期:2017-07-01 00:00:00

  • Fibrate pharmacogenomics: expanding past the genome.

    abstract::Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0140

    authors: House JS,Motsinger-Reif AA

    更新日期:2020-03-01 00:00:00

  • Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.

    abstract:AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.7.847

    authors: Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

    更新日期:2008-07-01 00:00:00

  • Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

    abstract::The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.117

    authors: Esplin ED,Oei L,Snyder MP

    更新日期:2014-11-01 00:00:00

  • Pharmacogenetic aspects in treatment of colorectal cancer--an update.

    abstract::Pharmacogenomic analyses will become crucial to predict patients' toxicity to treatment and will also help to predict the tumor response. Processes of drug metabolism, drug efflux, DNA-repair and characteristics of drug targets are critical checkpoints of drug efficacy. These crucial pathways for drug action have been...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.4.6.767.22825

    authors: Stoehlmacher J,Goekkurt E,Lenz HJ

    更新日期:2003-11-01 00:00:00

  • Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.

    abstract:AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.14.52

    authors: Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

    更新日期:2014-05-01 00:00:00

  • Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity.

    abstract::The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.6.4.419

    authors: Aubrecht J,Caba E

    更新日期:2005-06-01 00:00:00

  • Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

    abstract::In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.44

    authors: Awada Z,Zgheib NK

    更新日期:2014-04-01 00:00:00

  • DEPTOR polymorphisms influence late complications in Type 2 diabetes patients.

    abstract::Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0058

    authors: Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

    更新日期:2019-08-01 00:00:00

  • Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

    abstract::Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.7.1109

    authors: Glunde K,Serkova NJ

    更新日期:2006-10-01 00:00:00

  • Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

    abstract:AIMS:Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is depende...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.163

    authors: Gordon MA,Zhang W,Yang D,Iqbal S,El-Khouiery A,Nagashima F,Lurje G,Labonte M,Wilson P,Sherrod A,Ladner RD,Lenz HJ

    更新日期:2011-01-01 00:00:00

  • Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.

    abstract::Interindividual variability in drug response and the emergence of adverse drug effects are the main causes of treatment failure in cancer therapy. Functional membrane drug transporters play important roles in altering pharmacokinetic profile, resistance to treatment, toxicity and patient survival. Pharmacogenetic stud...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.165

    authors: Jabir RS,Naidu R,Annuar MA,Ho GF,Munisamy M,Stanslas J

    更新日期:2012-12-01 00:00:00

  • Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

    abstract:AIM:Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS:A linear mixed effect model compared voriconazole dose-corrected trough concentrations...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.53

    authors: Hicks JK,Crews KR,Flynn P,Haidar CE,Daniels CC,Yang W,Panetta JC,Pei D,Scott JR,Molinelli AR,Broeckel U,Bhojwani D,Evans WE,Relling MV

    更新日期:2014-06-01 00:00:00

  • SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.

    abstract:AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.105

    authors: Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

    更新日期:2014-01-01 00:00:00

  • CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

    abstract:AIMS:Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme act...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.112

    authors: Ruiter R,Bijl MJ,van Schaik RH,Berns EM,Hofman A,Coebergh JW,van Noord C,Visser LE,Stricker BH

    更新日期:2010-10-01 00:00:00

  • Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics.

    abstract::Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.12.1809

    authors: Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

    更新日期:2008-12-01 00:00:00

  • A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention.

    abstract::Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2019-0118

    authors: Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

    更新日期:2020-01-01 00:00:00

  • Applications of biochip and microarray systems in pharmacogenomics.

    abstract::A DNA microarray system is usually comprised of DNA probes formatted on a microscale on a glass surface (chip), plus the instruments needed to handle samples (automated robotics), to read the reporter molecules (scanners) and analyse the data (bioinformatic tools). Biochips are formed by in situ (on chip) synthesis of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.1.3.289

    authors: Jain KK

    更新日期:2000-08-01 00:00:00

  • Genetics of antipsychotic-induced weight gain: update and current perspectives.

    abstract::Antipsychotic medications are used to effectively treat various symptoms for different psychiatric conditions. Unfortunately, antipsychotic-induced weight gain (AIWG) is a common side effect that frequently results in obesity and secondary medical conditions. Twin and sibling studies have indicated that genetic factor...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,meta分析

    doi:10.2217/pgs.13.207

    authors: Kao AC,Müller DJ

    更新日期:2013-12-01 00:00:00

  • Pharmacogenetic considerations with dichloroacetate dosing.

    abstract::The investigational drug dichloroacetate (DCA) is a metabolic regulator that has been successfully used to treat acquired and congenital metabolic diseases and, recently, solid tumors. Its clinical use has revealed challenges in selecting appropriate doses. Chronic administration of DCA leads to inhibition of DCA meta...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2015-0012

    authors: James MO,Stacpoole PW

    更新日期:2016-05-01 00:00:00